CLINICAL_TRIALS
trial_result
· 2016-02-25
Clinical Trial Update: Vismodegib in Treating Patients With Recurrent or Refractory Medulloblastoma [Phase 2]
Summary
Phase 2 study of vismodegib in adults with recurrent or refractory medulloblastoma completed; results posted in 2016.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: National Cancer Institute (NCI) | Conditions: Adult Medulloblastoma | Phase 2 | Status: COMPLETED | Results posted: 2016-02-25